A proposed new paradigm for an anti-AIDS tolerogenic vaccine
Until now, despite 30 years of intensive work, the RV144 human immunodeficiency virus (HIV) vaccine trial initiated in 2003 remains so far the most protective vaccine prototype of all those tested (32% reduction in the infection rate three years after the vaccination) and the HIV epidemic is still s...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2022-04-01
|
| Series: | Exploration of Immunology |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/ei/Article/100346 |
| _version_ | 1818126724791009280 |
|---|---|
| author | Christine Jacomet |
| author_facet | Christine Jacomet |
| author_sort | Christine Jacomet |
| collection | DOAJ |
| description | Until now, despite 30 years of intensive work, the RV144 human immunodeficiency virus (HIV) vaccine trial initiated in 2003 remains so far the most protective vaccine prototype of all those tested (32% reduction in the infection rate three years after the vaccination) and the HIV epidemic is still spreading worldwide. In addition, antiretroviral therapy (ART) for people living with HIV is given for life as no other pharmacological intervention has allowed to maintain an undetectable viral load after ART withdrawal. Pr Andrieu and colleagues discovered tolerogenic CD8+T-cells that suppress simian immunodeficiency virus (SIV) specific activation, ensuing SIV reverse transcription suppression and viral replication-defective in Chinese macaques vaccinated by intragastric route with inactivated SIV particles + Lactobacillus rhamnosus. Moreover, in HIV-infected elite controllers with specific genetic features (HLA-1-Bw4-80i and KIR3DL1 genes), Pr Andrieu found out that similar tolerogenic CD8+T-cells suppress in the same manner HIV-specific activation, HIV reverse transcription, and HIV replication. These data justify the development of a tolerogenic vaccine composed of inactivated HIV particles + Lactobacillus rhamnosus that could be used as a preventive or therapeutic vaccine. |
| first_indexed | 2024-12-11T07:06:01Z |
| format | Article |
| id | doaj.art-fd9f76912b54401d85ba76aae83bb718 |
| institution | Directory Open Access Journal |
| issn | 2768-6655 |
| language | English |
| last_indexed | 2024-12-11T07:06:01Z |
| publishDate | 2022-04-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Immunology |
| spelling | doaj.art-fd9f76912b54401d85ba76aae83bb7182022-12-22T01:16:29ZengOpen Exploration Publishing Inc.Exploration of Immunology2768-66552022-04-012221121910.37349/ei.2022.00046A proposed new paradigm for an anti-AIDS tolerogenic vaccineChristine Jacomet0https://orcid.org/0000-0003-0794-6934Infectious and tropical disease department, COREVIH Auvergne Loire, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, FranceUntil now, despite 30 years of intensive work, the RV144 human immunodeficiency virus (HIV) vaccine trial initiated in 2003 remains so far the most protective vaccine prototype of all those tested (32% reduction in the infection rate three years after the vaccination) and the HIV epidemic is still spreading worldwide. In addition, antiretroviral therapy (ART) for people living with HIV is given for life as no other pharmacological intervention has allowed to maintain an undetectable viral load after ART withdrawal. Pr Andrieu and colleagues discovered tolerogenic CD8+T-cells that suppress simian immunodeficiency virus (SIV) specific activation, ensuing SIV reverse transcription suppression and viral replication-defective in Chinese macaques vaccinated by intragastric route with inactivated SIV particles + Lactobacillus rhamnosus. Moreover, in HIV-infected elite controllers with specific genetic features (HLA-1-Bw4-80i and KIR3DL1 genes), Pr Andrieu found out that similar tolerogenic CD8+T-cells suppress in the same manner HIV-specific activation, HIV reverse transcription, and HIV replication. These data justify the development of a tolerogenic vaccine composed of inactivated HIV particles + Lactobacillus rhamnosus that could be used as a preventive or therapeutic vaccine.https://www.explorationpub.com/Journals/ei/Article/100346hivvaccinecd8+t-cells |
| spellingShingle | Christine Jacomet A proposed new paradigm for an anti-AIDS tolerogenic vaccine Exploration of Immunology hiv vaccine cd8+t-cells |
| title | A proposed new paradigm for an anti-AIDS tolerogenic vaccine |
| title_full | A proposed new paradigm for an anti-AIDS tolerogenic vaccine |
| title_fullStr | A proposed new paradigm for an anti-AIDS tolerogenic vaccine |
| title_full_unstemmed | A proposed new paradigm for an anti-AIDS tolerogenic vaccine |
| title_short | A proposed new paradigm for an anti-AIDS tolerogenic vaccine |
| title_sort | proposed new paradigm for an anti aids tolerogenic vaccine |
| topic | hiv vaccine cd8+t-cells |
| url | https://www.explorationpub.com/Journals/ei/Article/100346 |
| work_keys_str_mv | AT christinejacomet aproposednewparadigmforanantiaidstolerogenicvaccine AT christinejacomet proposednewparadigmforanantiaidstolerogenicvaccine |